Biological Drug Api Manufacturing Services Market Set To Grow To $9.9 Bn By 2027

14 August 2018
Pharma

Visiongain has launched a new pharma report Biological Drug API Manufacturing Services World Industry and Market Predictions 2017-2027:
Analysis and Forecasts for Mammalian Cell Cultures, Microbial Fermentations, Other Expression Systems, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccines and Geography

The pharmaceutical industry is one of the largest and most consistent markets in the world. In order to meet the growing demand for pharmaceutical medications in an ever-growing population, companies are increasingly turning to API manufacturing originations. These organizations utilize the latest in biotechnology research to provide pharmaceutical companies with the raw biological components they need to thrive.

Biotech API manufacturing is the term used to describe the process of creating the basic components used to produce a pharmaceutical product for the biotech industry. The process of creating a pharmaceutical product, for example a medication, requires that components be manufactured first in the primary manufacturing process, before the drug can be created. APIs or active pharmaceutical ingredients are main components needed to build a product in the secondary manufacturing process. In the past, biotech APIs were usually manufactured in-house by pharmaceutical companies, but the current trend is to outsource biotech API manufacturing to CMOs (contract manufacturing organisations) or for a large pharmaceutical company to buy a smaller CMO to make use of its in-house manufacturing service. The reason in-house manufacturing is less common now is due to the high cost of the facilities and infrastructure needed for produce APIs. APIs can be of two types- a small molecule API created by chemical synthesis, or a large biologic, created through fermentation processes.

The visiongain report analyst commented “The outsourcing of biotech API contract manufacturing to contract manufacturing organizations around the world offers a number of benefits. As pharmaceutical companies around the world aim to cut costs in an increasingly crowded market CMOs offer scheduled and affordable services; without the high cost associated with building new manufacturing facilities. Contract manufacturing organizations also benefit smaller pharmaceutical companies, who outsource to access expertise and gain entry to markets they otherwise would not be able to reach; particular in emerging nations where the industry is on a rapid rise. Ultimately biotech API contract manufacturing helps to increase the interconnected nature of the pharmaceutical industry benefiting a number of groups as in continues to grow in the ever expanding pharmaceutical industry.”

Leading companies who are providing biological API manufacturing services featured in the report include Lonza, DSM Biologics, Boehringer Ingelheim BioXcellence, Celltrion. Sandoz, Lonza, AbbVie Contract Manufacturing, GSK Biopharmaceuticals, Samsung BioLogics and Cytovance Biologics

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever